China
Africa
Explore chapters and articles related to this topic
Conducting a Violence Risk Assessment
Published in Brian Van Brunt, Chris Taylor, Understanding and Treating Incels, 2020
This summary involves reporting information back to the referral source to put the plan into place. This occurs after the assessment is completed and can happen in the form of letter, phone call, or formalized report. This brings together the clinical formulation for risk along with the scenarios to create a clear and useful communication to allow the referral source to make decisions about what comes next for the client.
Doing and researching aesthetic work in the visual domain
Published in Alan Bleakley, Educating Doctors’ Senses Through the Medical Humanities, 2020
Research data were gathered in a number of ways and in differing forums: Public seminar and debate, and conference presentations: these formal settings, documented through videotaping, audiotaping and notes, involved framing of typical episodes of clinical and aesthetic judgements in the visual domain, to which invited audiences of doctors and artists responded.‘Thinking aloud’ work-based exchanges (artists to clinics and doctors to studios). These allowed practitioners to swap live practices and stories. The deliberative and reflective processes were documented through extensive notes.Doctors talking to clinical images such as X-rays, pathology slides and photographs of skin conditions. These model typical clinical formulation responses and were audiotaped and transcribed.Minuted review and round table discussions progressing models and insights with the project convenor, a medical educator and psychologist. This was an iterative process.
Victims and survivors
Published in John C. Gunn, Pamela J. Taylor, Forensic Psychiatry, 2014
Pamela J Taylor, Sharif El-Leithy, John Gunn, Felicity Hawksley, Michael Howlett, Gillian Mezey, David Reiss, Jenny Shaw, Jonathan Shepherd, Nicola Swinson, Pamela J Taylor, Jayne Zito, Felicity de Zulueta
Perhaps for clinical purposes, the important issue is less one of the frequency of a relationship between military experience and PTSD, but more an acknowledgement that, for at least some returning veterans, psychological problems are a major difficulty and, where so, in many cases also for their families and wider communities through intoxication or antisocial actions. Friedman (2006) offers a useful clinical formulation and treatment strategy.
Validity assessment in clinical neuropsychology practice: evaluating and managing noncredible performance
Published in Brain Injury, 2023
The second half of the book focuses on specific areas of practice and this format allows the reader to dip into their area of practice. This does reveal a limitation of the volume as it is written primarily with a North American audience in mind and so contains chapters specific to practitioners based in the USA. There is still information to be gleaned for all readers from these chapters however, with provision of practical examples which allow generalization to other settings, including the important consideration of the use of validity tests with culturally diverse individuals. There is, of course, a chapter on mild brain injury a population in which there has been a strong focus of validity assessment in the medicolegal setting. This, however, highlights the value and strength as the chapter contains up-to-date literature and a practical ‘how to’ focus, including treatment. Chapters on the validity assessment in individuals with psychiatric and in memory clinics provide suggestions regarding different cutoffs for validity tests and consideration of specificity; the assumption that depression and anxiety will lead to invalid performance is challenged. The chapter on patients with somatic/functional disorders follows the overall format of the book with up-to-date evidence to inform clinical practice, how to interpret results and develop a clinical formulation, and then use this information to assist the patient. Overall, the practical information supported by the literature will allow clinicians to be more confident in their conclusions and ultimately inform better diagnostic and treatment outcomes.
A patent review of MAT2a inhibitors (2018–2021)
Published in Expert Opinion on Therapeutic Patents, 2022
Stephen J. Atkinson, Laura Evans, James S. Scott
Looking back at the chemical equity covered by this review, there are a number of noteworthy advances in the field over the last 4 years. The initial patent applications from Agios [11,12] and Ideaya [22] on the pyrazolo[1,5-a]pyrimidin-7(4H)-one and quinazolinone templates, supported by the subsequent publications on these templates, highlight the success of targeting the allosteric binding pocket which was initially disclosed by Pfizer using the molecule PF-9366 [8]. Agios have clearly shown that potent inhibition of MAT2a can lead to downstream antiproliferative effects in MTAP KO cell lines, which is directly correlated with the downstream inhibition of PRMT5 under high MTA concentrations. This has been shown to translate into in vivo xenograft and PDX model efficacy in sensitive MTAP-deficient tumors [13,14]. This suggests that the feedback loop triggered by a reduction in SAM concentration and leading to upregulation of MAT2a gene expression, can be overcome by optimized inhibitors once suitable in vivo target engagement is obtained. Further analysis of the AG-270 development candidate profile reveals favorable pharmacokinetics, although it was noted that solubility was low and permeability in the Caco-2 assay was indeterminable due to low recovery. However, a spray dried dispersion formulation allowed good preclinical bioavailability, likely enabling a route to a viable clinical formulation. Agios report a good off-target selectivity profile, although highlight some inhibition of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) and organic anion transporting polypeptide 1B1 (OATP1B1) [14].
Associations between participant characteristics, digital intervention engagement and recovery outcomes for participants accessing ‘Breaking Free Online’ at ‘Change Grow Live’
Published in Journal of Substance Use, 2021
Sarah Elison-Davies, Karen Hayhurst, Andrew Jones, Zoe Welch, Glyn Davies, Jonathan Ward
BFO delivers these BCTs (see Table 1) in a tailored manner through utilizing data captured from a baseline assessment that users of the program are required to complete, which contains the ‘Recovery Progression Measure’ (RPM: Elison, Davies et al., 2016). The BFO program uses baseline RPM data to populate a visual depiction of a six-domain biopsychosocial model, the ‘Lifestyle Balance Model’ (LBM – see Figure 1: Davies et al., 2015), which forms the theoretical underpinnings of BFO and is based on the five-factor model used in cognitive behavioral therapy (Greenberger & Padesky, 1995; Williams & Chellingsworth, 2010). The LBM provides a clinical formulation to help the individual to understand the specific issues that may be associated with their substance misuse. The LBM also provides access to the BCTs within BFO.